Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243189 | 0.80 | L3MBTL1 (0.53) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL11241398 | 0.77 | ALDH1A1 (0.49) | SMN1; SMN2POLBATMALDH1A1HSD17B10 | |
| SCHEMBL12520053 | 0.77 | ALDH1A1 (0.53) | SMN1; SMN2POLBATMALDH1A1HSD17B10 | |
| SCHEMBL8827563 | 0.76 | TSHR (0.45) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL12667884 | 0.74 | SMN1; SMN2 (0.44) | SMN1; SMN2POLBATMALDH1A1HSD17B10 | |
| SCHEMBL14349488 | 0.69 | ATM (0.59) | SMN1; SMN2ATMALDH1A1HTTL3MBTL1 | |
| SCHEMBL423971 | 0.69 | — | — | |
| SCHEMBL423972 | 0.69 | — | — | |
| SCHEMBL9040661 | 0.67 | ATM (0.56) | SMN1; SMN2POLBATMALDH1A1L3MBTL1 | |
| SCHEMBL429744 | 0.67 | ATM (0.56) | SMN1; SMN2POLBATMALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608052-B2 | An mono or polycyclic aromatic or heteroaromatic carbamate or urea or thiacarbamoyl derivatives; inhibit production of cytokines involved in inflammatory processes | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-19 | — | — | US | claimed |
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | claimed |
| EP-1381594-A1 | UREA COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6608052-B2 | An mono or polycyclic aromatic or heteroaromatic carbamate or urea or thiacarbamoyl derivatives; inhibit production of cytokines involved in inflammatory processes | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-19 | — | — | US | disclosed |
| WO-2002083642-A1 | COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | MPO, EPX, PTGES | SMN1; SMN2 4600/4885POLB 2563/4885ATM 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.